Compare Alcon AG (ALC) vs Gogoro Inc (GGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Gogoro Inc — how do they compare? Alcon AG trades at $66.93 (market cap $32.69B), while Gogoro Inc trades at $3.9 (market cap $76.99M). The key difference: Alcon AG is far larger — about 424.6× Gogoro Inc's market cap, and Alcon AG pays a 0.54% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.
| ALC | GGR | |
|---|---|---|
Market Cap | $32.69B | $76.99M |
Sector | Health | Technology |
52-Week High | $92.22 | $7.89 |
52-Week Low | $62.02 | $2.74 |
Enterprise Value | $36.28B | $379.44M |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
GGR trades at $3.94, down 0.51% today, with a bearish technical signal and negative profitability. The company reported a net loss of $79.97 million on $281.48 million revenue for 2025, though operating cash flow improved to $35.90 million. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvements and growth initiatives.
The outlook remains challenging due to persistent losses and negative ROE, but low valuation multiples and projected cash flow improvements offer potential upside if execution improves. Key risks include sustained unprofitability and competitive pressures in the mobility sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
